Search Results

War on Melanoma™ Public Health & Education Campaign

• Authors : Melanoma Research Foundation; Oregon Health and Science University; Sancy A Leachman, MD, PhD, Principal Investigator

• Source: Educational Program for the Early Detection of Melanoma in Oregon

Record details

Duration of Anti-PD-1 Therapy in Metastatic Melanoma (STOP-GAP)

• Authors : Melanoma and Skin Cancer Trials Limited

• Source: A Randomized Phase III Trial of the Duration of Anti-PD-1 Therapy in Metastatic Melanoma

Record details

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

• Authors : Melanoma Research Alliance; California Institute for Regenerative Medicine (CIRM); City of Hope National Medical Center ...

• Source: Phase I Dose Escalation Study of Systemically Administered IL13Ra2 Chimeric Antigen Receptor (CAR) T Cells After a Nonmyeloablative Conditioning Regimen in Patients With Metastatic

Record details

Liquid Biomarker Study in Melanoma and Non-Melanoma Skin Cancers

• Authors : National Center for Advancing Translational Sciences (NCATS)

• Source: Liquid Biomarker Study in Melanoma and Non-Melanoma Skin Cancers

Record details

Neoadjuvant Darovasertib in Primary Uveal Melanoma

• Source: A Randomized, Phase 3, Open-label Study of Neoadjuvant Darovasertib in Subjects With Primary Non-metastatic Uveal Melanoma (OptimUM-10)

Record details

Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery

• Source: A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High Dose Interferon a-2b for Resected High Risk MelanomaMcLouth LE, Zheng Y, Smith

Record details

Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Melanoma

• Source: Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of MelanomaLiang X, Pfeiffer RM, Li WQ, Brossard M, Burke LS,

Record details

Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma

• Source: Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma

Record details

Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

• Source: A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients With Advanced MelanomaHodi FS, Lee S, McDermott DF, Rao UN, Butterfield LH, Tarhini AA, Leming P,

Record details

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma

• Source: Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV

Record details